Crohn's disease news from FierceBiotech
News
ALSO NOTED: Apoptos gains $28M Series A; Commonwealth Biotechnologies venture to recruit 1,000 chemists in China;and much more.
> Apoptos will get a two-tranche Series A of $28 million from a group of investors that includes Venrock, ARCH Venture Partners, OrbiMed Advisors, and Advanced Technology Ventures. The developer Read more...
UCB CEO plots strategy following Cimzia approval
Fresh off the FDA's approval of Cimzia for Crohn's disease, UCB chief executive Roch Doliveux forecast a swift regulatory success in Europe. Cimzia is one of the most closely watched late-stage Read more...
ALSO NOTED: FDA approves UCB's Cimzia; MacroChem acquires Virium; and much more...
> The FDA has approved UCB's monoclonal antibody Cimzia for the treatment of moderate to severe Crohn's disease. Cimzia's approval was Read more...
VC: Alimera land $30M in third round
Alimera land $30M in third round VENTURE CAPITALCOMPANY AMOUNT/ROUNDLEAD INVESTORSDESCRIPTIONAlimera SciencesAtlanta, Read more...
TxCell rounds up $16M in second round
France's TxCell has booked up €10.5 million (about $16 million) in a second round of venture funding. Previous investors Auriga Partners, AXA Private Equity, Bioam Gestion, CDC Innovation and Read more...
Ocera gins $35.5M in third venture round
San Diego-based Ocera Therapeutics has lined up $35.5 million in its third venture round to push the further development of its lead--and only--therapy: AST-120, which was in-licensed from Japan's Read more...
EMEA shoots down UBC's Cimzia
It looks like UBC has struck out in the EU. The EMEA told the company that the Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion on Cimzia, a treatment for Crohn's Read more...
FDA committee backs Tysabri for Crohn's
Elan and Biogen Idec have won the backing of an FDA expert committee in its quest to gain regulatory approval for Tysabri as a therapy for Crohn's disease. The backing came for the use of Tysabri for Read more...
Press Release: MedInsight Announces Clinical Trial Results of Low-dose Naltrexone
Press Release: MedInsight Announces Clinical Trial Results of Low-dose Naltrexone
Read more...Naltrexone effective in new Crohn's study
Researchers say that low-dose naltrexone proved an effective therapy against Crohn's disease. According to the study, 89 percent of treated patients experienced significant improvement in their symptoms, and two-thirds experienced remission.
"This is a novel, yet effective, approach to treating a common disease," says Jill Smith, Professor of Gastroenterology at Hershey …
Read more...Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets